AMP-224

· MedImmune LLC

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for AMP-224, covering 2016-09-05 to 2019-02-22. Get the full timeline:

Most recent: Clinical Trial Update: AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer [Phase 1]